AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03316599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells
Study NCT03316599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ficlatuzumab
Description: It is selective recombinant humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G subclass 1 monoclonal antibody which blocks the MET tyrosine kinase receptor.
Study NCT03161015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT440
Description: Oral
Study NCT03313440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High wheat fiber
Description: Daily increased fiber intake by 18-22 grams/day. Products are provided in boxes that must be consumed each day during the intervention.
Study NCT03313440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low fiber
Description: Control low fiber intervention. Products are provided in boxes that must be consumed each day during the intervention.
Study NCT03756805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: upper airway stimulation
Description: One group of patients with UAS
Study NCT03756805 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous positive airway pressure
Description: One group of patients with CPAP
Study NCT02940158 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 1/4 cup- Small red lentil
Study NCT01665989 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Visits with a dietitian at nutrition services at MGH
Study NCT01243567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution
Description: Bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution (GANfort®) administered to each eye requiring treatment, once daily in the evening for 3 months.
Study NCT01243567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost 0.005% ophthalmic solution
Description: Latanoprost 0.005% ophthalmic solution (Xalatan®) administered to each eye requiring treatment, once daily in the evening for 3 months.
Study NCT00607854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibritumomab Tiuxetan (Zevalin)
Description: Conditioning regimen followed by allogeneic hematopoietic stem cell transplantation.~Ibritumomab Tiuxetan(Zevalin): 0.4 mCi/kg IV at day -14 (Day 0 is the transplantation)
Study NCT02267954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu edited
Description: The menu is edited to change price label to 50% of actual value and calorie label to 50% of the actual value, along with other changes.
Study NCT01152515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Control group : stopping of propofol and remifentanil infusion Remifentanil group : stopping of propofol and maintenance of remifentanil infusion
Study NCT01812369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEMCITABINE CISPLATINE
Study NCT01812369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF
Study NCT03926312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart device-based cardiac rehabilitation
Description: A smart device coupled with remote monitoring will be used to increase physical activity of patients after myocardial infarction with a history of low physical activity.
Study NCT01301105 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Stress Reduction (MBSR)
Description: 8 week class in stress reduction through instruction in mindfulness related techniques.
Study NCT01301105 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Enhancement Program (HEP)
Description: 8-week intervention designed to be structurally equivalent to MBSR but without a mindfulness component. Consists of nutrition, functional movement, physical activity, and music therapy.
Study NCT03580824 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21 in Matrix- M adjuvant vaccine
Description: R21: Protein particle malaria vaccine candidate in Matrix-M: Saponin based vaccine adjuvant.
Study NCT06000306 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Digital Droplet PCR
Description: Measurable residual disease Monitoring by Digital Droplet PCR in the Early Posttransplant Period
Study NCT03246490 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: All Participants
Description: all participants will participate in the same protocol involving drinking alcohol to a .08 g% blood alcohol level
Study NCT04251975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Description: In this group of patients (CPAP group) will be prescribed CPAP treatment at an optimal pressure. It will be performed a CPAP titration with an automatic or manual CPAP according to usual clinical practice
Study NCT02940158 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 1/4 cup- Small green lentil
Study NCT02126566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Administration of light therapy - measurement of results before and after therapy
Study NCT02922166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRX246
Description: oral capsule
Study NCT02922166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsule
Study NCT01361932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video of ED discharge instructions for patient's ED discharge diagnosis
Description: Link provided for a website of 38 ED discharge instruction videos, based on ED discharge diagnosis; patients in study group encouraged to view it upon returning home. Three key questions asked by RA 1 to 5 days later, via phone call, and answers scored.
Study NCT04299763 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oat Beta-glucan as a Supplement in Type 2 Diabetics
Description: 44 subjects were randomized into two groups, placebo (PL) and β-glucan (BG). Each person received a package with a supplement sufficient for 12 weeks, adding 5 g of supplement to breakfast, which could contain beta-glucan or not. Blood and stool samples were requested at the beginning and at the end of the intervention.
Study NCT04299763 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oat Beta-glucan as a Supplement in Type 2 Diabetics
Description: 44 subjects were randomized into two groups, placebo (PL) and β-glucan (BG). Each person received a package with a supplement sufficient for 12 weeks, adding 5 g of supplement to breakfast, which could contain beta-glucan or not. Blood and stool samples were requested at the beginning and at the end of the intervention.
Study NCT03721809 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood samples
Description: There are 3 specific blood sampling times for each patient, on D1, D2 and D5 (D1 being the day of inclusion): cytokine samples (IL-1β, IL-6, IL-10, TNF-α, IFN-gamma) on 5ml dry tube.~On D1, a 2.5ml PAXgene tube will also be taken for each patient.
Study NCT01099657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Hypnosis for chronic pain
Description: At the time of their clinic visit,the subject will answer pain and anxiety questionnaires before experiencing Virtual Reality Hypnosis. After VRH, the will again answer Pain and anxiety questionnaires.
Study NCT01099657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Distraction for Chronic Pain
Description: At the time of their clinic visit,the subject will answer pain and anxiety questionnaires before experiencing Virtual Reality Distraction. After VRD, the will again answer Pain and anxiety questionnaires.
Study NCT00450736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Study NCT00450736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT00450736 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT01840358 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observation of hypoglycemias frequency 3 days before and after pump initiation
Study NCT02395055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab (BCD-057)
Description: Adalimumab is a monoclonal antibody against tumor necrosis factor alpha
Study NCT02395055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab (Humira)
Description: Adalimumab is a monoclonal antibody against tumor necrosis factor alpha
Study NCT02940158 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 1/4 cup- corn
Study NCT02940158 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 1/4 cup- macaroni
Study NCT02940158 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 1/4 cup- white potato
Study NCT02940158 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 1/4 cup- white rice
Study NCT01711593 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bronchoscopy, Segmental Allergen Challenge and Bronchoalveolar Lavage
Description: On the first bronchoscopy day,BAL will first be performed in the lingual without instillation of diluent or allergen. A 2ml aliquot of isotonic diluent is instilled into the right upper lobe.The procedure is repeated in the right middle lobe with instillation of 2ml of standardized cat or mite allergen solution. A test dose concentration of allergen is administered first consisting of 2 ml of allergen at 1/10th(Cat,D.farinae)or 1/30th(D.pteronyssinus)the threshold concentration.If on visual inspection through the bronchoscope there is no evidence of mucosal inflammation after 2 minutes a second segmental allergen challenge will be done in the right middle lobe using 2ml of full-dose allergen at the threshold concentration(Cat,D.farinae)or 1/3 the threshold concentration(D.pteronyssinus). This dose will be predetermined by quantitative skin prick testing.A second bronchoscopy is performed 24 hours after delivery of allergen extract and diluent to obtain BAL fluid from the RUL and RML.
Study NCT01711593 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phlebotomy
Description: 200 (40 teaspoons) ml of blood will be obtained from the subjects to collect different leukocyte populations. A second 200 ml of blood will be obtained from the Track 2 subjects 4 weeks later for isolation of T lymphocytes for functional studies.
Study NCT02667782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Description: Recruited subjects that are randomly allocated into the MBSR group will have an intensive face-to-face (F-T-F) teaching-learning program that is focused on stress reduction. After that, there will be some regular telephone follow-ups for a closed group of 10-15 participants. Subjects would receive four consecutive weekly F-T-F sessions, then a weekly telephone follow-up for three months in combination with an F-T-F session once a month. The Interventionist will be an experienced mindfulness therapist who is qualified to deliver both MBSR and MBCT.
Study NCT03580317 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sham EA+Carbamazepine
Description: Selection of points and locations: the non-meridional points which are means to the points beside 5-10mm of the real acupoints (avoid the trigger point) in the EA group will be selected and needled with more shallow acupuncture (the depth of needling is about 1-2mm).~The operation of shame EA: The HuaTuo SDZ-ⅡB acupoint neural stimulator with damaged electrode wires will be selected to connect the points next to the Xia-guan(ST7) and Quan-liao (SI18) , He-gu (LI4) and Wai-guan(TE5).The frequency, intensity and retaining time will be same as EA group, The subjects can see the display screen and parameter settings of stimulator, however there is no electricity output in fact.~The dosage and frequency of oral carbamazepine tablets are same as above part.
Study NCT03580317 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham EA+Placebo
Description: The points selection, positioning and manipulation are same as Shame EA+ Carbamazepine group，placebo are cooperated taken of dose 0.1g, thrice daily.
Study NCT02667782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Description: Recruited subjects that are randomly allocated into the MBCT group will have an intensive face-to-face (F-T-F) teaching-learning program that is focused on cognitive therapy. After that, there will be some regular telephone follow-ups for a closed group of 10-15 participants. Subjects would receive four consecutive weekly F-T-F sessions, then a weekly telephone follow-up for three months in combination with an F-T-F session once a month. The Interventionist will be an experienced mindfulness therapist who is qualified to deliver both MBSR and MBCT.
Study NCT02787590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Study NCT02787590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo (for Simvastatin)
Study NCT01219933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: starting dose >/= 1 mg and \</= 20 mg orally daily, according to dose-reduction schedule
Study NCT01219933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: background therapy: 8 mg/kg iv every 4 weeks
Study NCT04524650 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: the level of vWF
Description: the peripheral level of vWF
Study NCT04218071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib at protocol-specified doses for given platelet count
Study NCT04218071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9-ING-41
Description: 9-
Study NCT05546255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: The recommended dose of Eribulin is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1
Study NCT05546255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobaplatin
Description: The recommended dose of lobaplatin is 25mg/m2 administered intravenously over on Days 1
Study NCT02177409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Study NCT02177409 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Study NCT02177409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02177409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03458858 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mixed Berry Diet
Description: Mixed Berry Treatment
Study NCT03458858 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Carbohydrate Control Jello
Description: Carbohydrate Control
Study NCT03458858 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fiber Enriched Jello
Description: Fiber Control
Study NCT03458858 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low Fiber Mixed Berry Juice
Description: Anthocyanin Control
Study NCT03657147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Video and Question Prompt List
Description: A short educational video will be presented on an iPad about the importance of encouraging patients to ask questions and to be involved during glaucoma visits to improve self-management skills. A question prompt list will also be completed where participants check questions of interest to ask the provider.
Study NCT02712424 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DAR-901
Study NCT02712424 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sterile saline placebo
Study NCT01586104 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo cardiac-sparing whole lung IMRT
Study NCT04202198 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A-PRF
Description: local anesthesia was administered followed by placement of a hole in the alveolar mucosa adjacent to mesial most recession tooth. tunneling instruments are used to elevate a full thickness tunnel upto the CEJ sparing the tip of the papilla.previously prepared PRF membranes are placed through the access hole and the flap is advanced. 5-0 polyglycolic acid sutures is used to secure the advanced flap.
Study NCT04202198 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pinhole surgical technique only
Description: local anesthesia was administered followed by placement of a hole in the alveolar mucosa adjacent to mesial most recession tooth. tunneling instruments are used to elevate a full thickness tunnel upto the CEJ sparing the tip of the papilla followed by advancement of the flap. 5-0 polyglycolic acid sutures is used to secure the advanced flap.
Study NCT00003847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biricodar dicitrate
Study NCT00003847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00003847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT03492216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives for negative EtG test
Description: Economic incentives are given to the study participant contingent on point-of-care (POC) urine ethyl glucuronide (EtG) \<300 ng/mL with the amount of the incentive escalating with each subsequent negative EtG test.
Study NCT03492216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives for positive IsoScreen test
Description: Economic incentives contingent on POC (IsoScreen) INH urine positive tests with the amount of the incentive escalating with each subsequent positive IsoScreen test.
Study NCT00299013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COLAL-PRED®
Description: COLAL-PRED 40, 60 or 80mg oral capsule, once daily for 8 weeks.
Study NCT01611857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Patients with advanced solid tumors will be treated with oral Tivantinib (120, 240, or 360 mg BID) daily for 14 days in cycles of 14 days.
Study NCT01611857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: The FOLFOX treatment regimen is started on Day 1 of each cycle and consists of 5-Fluorouracil (5-FU) 400 mg/m\^2, 5-FU continuous IV 2400 mg/m\^2 over 46 hours, leucovorin 400 mg/m\^2 IV, and oxaliplatin 85 mg/m\^2.
Study NCT02940158 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 1/2 cup- small red lentil
Study NCT02940158 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 1/2 cup- small green lentil
Study NCT02940158 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 1/2 cup- corn
Study NCT02940158 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 1/2 cup- macaroni
Study NCT02940158 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 1/2 cup- white potato
Study NCT02940158 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 1/2 cup- white rice
Study NCT00103207 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Study NCT02759939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video + Prompt Card
Description: 1. A brief video (available in English and Spanish) intended to be viewed by patients immediately before the health care visit. The video aims to enhance patients' motivation, skills, and self-efficacy to ask their health care providers three specific questions: (1) What are my options? (2) What are the pros and cons of those options? and (3) How likely are those pros and cons to happen to me?~2. A prompt card (available in English and Spanish) intended to be provided to patients when they view the video and kept. The card aims to remind patients of the three questions presented in the video.
Study NCT02759939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aids + Training
Description: 1. Seven one-page decision aids on contraceptive methods (available in English and Spanish) intended to be used by health care providers with patients during the health care visit.~2. A five-minute training video and accompanying written guidance (available in English) intended to be reviewed by health care providers before implementing the decision aids (and as frequently as desired thereafter). The training aims to enhance providers' motivation, skills, and self-efficacy to use the decision aids to facilitate shared decision-making in the health care visit.
Study NCT02968277 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeWalker Upright
Description: LifeWalker (LW) upright walker
Study NCT02968277 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Predicate Device
Description: Individual's personal walker
Study NCT02513212 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Potassium Oxalate
Description: Professionally applied liquid
Study NCT02513212 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Stannous fluoride paste
Description: SnF2 Paste
Study NCT02513212 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Manual toothbrush
Description: Marketed manual toothbrush
Study NCT02513212 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Power toothbrush
Description: Marketed power toothbrush